- Home
- BNR vs CMRX Comparison
BNR vs CMRX Comparison
Compare BNR & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNR
- CMRX
- Stock Information
- Founded
- BNR 2014
- CMRX 2000
- Country
- BNR China
- CMRX United States
- Employees
- BNR N/A
- CMRX N/A
- Industry
- BNR Medical Specialities
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- BNR Health Care
- CMRX Health Care
- Exchange
- BNR Nasdaq
- CMRX Nasdaq
- Market Cap
- BNR 69.6M
- CMRX 354.5M
- IPO Year
- BNR 2020
- CMRX 2013
- Fundamental
- Price
- BNR $6.66
- CMRX $3.94
- Analyst Decision
- BNR
- CMRX Strong Buy
- Analyst Count
- BNR 0
- CMRX 2
- Target Price
- BNR N/A
- CMRX $8.50
- AVG Volume (30 Days)
- BNR 5.1K
- CMRX 1.4M
- Earning Date
- BNR 03-27-2025
- CMRX 02-27-2025
- Dividend Yield
- BNR N/A
- CMRX N/A
- EPS Growth
- BNR N/A
- CMRX N/A
- EPS
- BNR N/A
- CMRX N/A
- Revenue
- BNR $72,832,704.00
- CMRX $159,000.00
- Revenue This Year
- BNR $52.90
- CMRX N/A
- Revenue Next Year
- BNR $48.35
- CMRX $1,690.28
- P/E Ratio
- BNR N/A
- CMRX N/A
- Revenue Growth
- BNR N/A
- CMRX N/A
- 52 Week Low
- BNR $2.62
- CMRX $0.75
- 52 Week High
- BNR $8.99
- CMRX $4.22
- Technical
- Relative Strength Index (RSI)
- BNR 50.28
- CMRX 66.29
- Support Level
- BNR $5.58
- CMRX $3.95
- Resistance Level
- BNR $6.85
- CMRX $4.22
- Average True Range (ATR)
- BNR 0.28
- CMRX 0.28
- MACD
- BNR -0.06
- CMRX -0.03
- Stochastic Oscillator
- BNR 62.01
- CMRX 74.55
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.